Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
PFE

Price
27.37
Stock movement down
-0.21 (-0.76%)
Company name
Pfizer Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - General
Market cap
155.62B
Ent value
275.86B
Price/Sales
2.49
Price/Book
-
Div yield
6.28%
Div growth
3.62%
Growth years
11
FCF payout
160.24%
Trailing P/E
20.03
Forward P/E
9.67
PEG
3.73
EPS growth
-4.36%
1 year return (CAGR)
6.75%
3 year return (CAGR)
-14.21%
5 year return (CAGR)
-4.78%
10 year return (CAGR)
0.12%
Last updated: 2026-03-11

iO Charts is a Seeking Alpha partner

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...
Covid-19 vaccine comments

BNT162b2, which was granted an emergency use authorization (EUA) in the U.S. in December 2020, and which contributed $154 million in sales in the fourth quarter

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.72
Dividend yield6.28%
Payout frequencyQuarterly
Maximum yield7.97%
Average yield4.96%
Minimum yield2.61%
Discount to avg yield21.04%
Upside potential26.65%
Yield as % of max yield78.88%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield6.28%
Current yield distribution26.51%
Yield at 100% (Min)2.61%
Yield at 90%3.15%
Yield at 80%3.37%
Yield at 50% (Median)4.60%
Yield at 20%6.56%
Yield at 10%6.91%
Yield at 0% (Max)7.97%

Dividend per share

Loading...
Dividend per share data
Years of growth11 years
CCC statusDividend Contender
Dividend per share1.72
Payout frequencyQuarterly
Ex-div date23 Jan 2026
EPS (TTM)1.37
EPS (1y forward)2.83
EPS growth (5y)-4.36%
EPS growth (5y forward)5.37%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
PFES&P500
DGR MR2.38%-13.74%
DGR TTM1.78%6.60%
DGR 3 years2.44%7.31%
DGR 5 years3.62%4.69%
DGR 10 years4.95%6.30%
DGR 15 years6.36%8.16%
Time since last change announced456 days
EPS growth (5y)-4.36%
EPS growth (5y forward)5.37%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM94.29%160.24%
Average--
Forward60.78%-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E20.03
Price to OCF24.48
Price to FCF34.04
Price to EBITDA11.58
EV to EBITDA20.53

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.49
Price to Book-
EV to Sales4.41

FINANCIALS

Per share

Loading...
Per share data
Current share count5.69B
EPS (TTM)1.37
FCF per share (TTM)0.80

Income statement

Loading...
Income statement data
Revenue (TTM)62.58B
Gross profit (TTM)44.01B
Operating income (TTM)15.44B
Net income (TTM)7.77B
EPS (TTM)1.37
EPS (1y forward)2.83

Margins

Loading...
Margins data
Gross margin (TTM)70.33%
Operating margin (TTM)24.67%
Profit margin (TTM)12.42%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.14B
Net receivables0.00
Total current assets42.90B
Goodwill71.26B
Intangible assets53.73B
Property, plant and equipment0.00
Total assets208.16B
Accounts payable0.00
Short/Current long term debt64.80B
Total current liabilities36.98B
Total liabilities121.39B
Shareholder's equity0.00
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)6.36B
Capital expenditures (TTM)1.78B
Free cash flow (TTM)4.57B
Dividends paid (TTM)7.33B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open27.84
Daily high27.86
Daily low27.20
Daily Volume27.8M
All-time high61.25
1y analyst estimate28.43
Beta0.41
EPS (TTM)1.37
Dividend per share1.72
Ex-div date23 Jan 2026
Next earnings date28 Apr 2026

Downside potential

Loading...
Downside potential data
PFES&P500
Current price drop from All-time high-55.31%-1.82%
Highest price drop-76.70%-56.47%
Date of highest drop2 Mar 20099 Mar 2009
Avg drop from high-31.77%-10.84%
Avg time to new high38 days12 days
Max time to new high5620 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
PFE (Pfizer Inc) company logo
Marketcap
155.62B
Marketcap category
Large-cap
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Employees
75000
SEC filings
CEO
Albert Bourla
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...